QIAGEN/$QGEN
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About QIAGEN
Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between applications in life sciences and molecular diagnostics. Qiagen generates nearly 90% of its revenue from consumables with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm's revenue (52% of 2024 sales), followed by EMEA (33%), and the Asia-Pacific (15%).
Ticker
$QGEN
Sector
Primary listing
NYSE
Employees
5,700
Headquarters
Website
QIAGEN Metrics
BasicAdvanced
$9.7B
24.10
$1.85
0.68
$0.25
0.56%
Price and volume
Market cap
$9.7B
Beta
0.68
52-week high
$51.88
52-week low
$37.63
Average daily volume
1.1M
Dividend rate
$0.25
Financial strength
Current ratio
2.6
Quick ratio
2.122
Long term debt to equity
44.917
Total debt to equity
58.289
Dividend payout ratio (TTM)
13.38%
Interest coverage (TTM)
24.86%
Profitability
EBITDA (TTM)
1,028.656
Gross margin (TTM)
80.27%
Net profit margin (TTM)
19.58%
Operating margin (TTM)
41.13%
Effective tax rate (TTM)
20.04%
Revenue per employee (TTM)
$360,000
Management effectiveness
Return on assets (TTM)
8.19%
Return on equity (TTM)
11.29%
Valuation
Price to earnings (TTM)
24.105
Price to revenue (TTM)
4.672
Price to book
2.65
Price to tangible book (TTM)
12.14
Price to free cash flow (TTM)
20.475
Free cash flow yield (TTM)
4.88%
Free cash flow per share (TTM)
2.181
Dividend yield (TTM)
0.56%
Forward dividend yield
0.56%
Growth
Revenue change (TTM)
5.32%
Earnings per share change (TTM)
334.36%
3-year revenue growth (CAGR)
-2.38%
10-year revenue growth (CAGR)
4.82%
3-year earnings per share growth (CAGR)
-6.35%
10-year earnings per share growth (CAGR)
14.53%
QIAGEN News
AllArticlesVideos
QIAGEN Unveils QIAsymphony Connect and Showcases New Precision Oncology Innovations at AMP 2025
Business Wire5 days ago
Seattle's Parse Biosciences to be acquired by Qiagen for $225M
GeekWire1 week ago
QIAGEN to acquire Parse Biosciences, expanding its Sample technologies portfolio into highly scalable single-cell solutions
Business Wire1 week ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for QIAGEN stock?
QIAGEN (QGEN) has a market cap of $9.7B as of November 14, 2025.
What is the P/E ratio for QIAGEN stock?
The price to earnings (P/E) ratio for QIAGEN (QGEN) stock is 24.1 as of November 14, 2025.
Does QIAGEN stock pay dividends?
Yes, the QIAGEN (QGEN) stock pays dividends to shareholders. As of November 14, 2025, the dividend rate is $0.25 and the yield is 0.56%. QIAGEN has a payout ratio of 13.38% on a trailing twelve-month basis.
When is the next QIAGEN dividend payment date?
The next QIAGEN (QGEN) dividend payment date is unconfirmed.
What is the beta indicator for QIAGEN?
QIAGEN (QGEN) has a beta rating of 0.68. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.